Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06062875 · ClinicalTrials.gov registry record · Phase 2
Effects of TNF Blockade on Human BPH/LUTS
A Phase 2 study of Benign Prostatic Hyperplasia (BPH), sponsored by Endeavor Health.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 70
- Enrollment target
- 1
- Study location
NCT06062875 is a Phase 2 study of Benign Prostatic Hyperplasia (BPH) that is actively recruiting participants, run by Endeavor Health. The registered enrollment target is 70 participants, below the 91-participant average among 3 other Benign Prostatic Hyperplasia (BPH) trials with a reported enrollment target (23% lower). The trial reports 1 study location across 1 state.
The verdict
NCT06062875, a Phase 2 study of Benign Prostatic Hyperplasia (BPH), is actively recruiting participants, sponsored by Endeavor Health.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 70 participants
- Enrollment target
- 1
- Study location
Study Summary
Specific Aim 1. To evaluate the efficacy of TNF antagonist action in BPH/LUTS Specific Aim 2. Define the consequences of TNF antagonist therapy on prostate tissue Specific Aim 3. Identify genetic predictors to stratify patients with differential response to TNF-antagonist therapy.
Conditions Studied
Interventions
- DRUG Adalimumab
Study Locations (1)
Illinois
- NorthShore University HealthSystem - Glenview
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 70 participants |
| Start Date | 2024-01-24 |
| Est. Completion | 2028-06-01 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06062875
The ClinicalTrials.gov registry entry for NCT06062875 describes a study currently listed as recruiting, categorized as Phase 2. The registered enrollment target is 70 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 91-participant average among 3 other Benign Prostatic Hyperplasia (BPH) trials with a reported enrollment target (23% lower). The listed sponsor is Endeavor Health, which has 94 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Benign Prostatic Hyperplasia (BPH) appearing as the primary indexed condition, and to 1 intervention - of which Adalimumab is the first listed.
NCT06062875 reports 1 study location spanning 1 distinct geographic area - top geographies include Illinois.
Frequently Asked Questions
What is clinical trial NCT06062875 about?
NCT06062875 is a clinical study titled "Effects of TNF Blockade on Human BPH/LUTS". Specific Aim 1. To evaluate the efficacy of TNF antagonist action in BPH/LUTS Specific Aim 2. Define the consequences of TNF antagonist therapy on prostate tissue Specific Aim 3. Identify genetic predictors to stratify patients with differential response to TNF-antagonist therapy.
What is the current status of trial NCT06062875?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 70 participants. The study started on 2024-01-24. Estimated completion is 2028-06-01.
What conditions does trial NCT06062875 study?
This clinical trial studies the following conditions: Benign Prostatic Hyperplasia (BPH).
What interventions are being tested in trial NCT06062875?
The interventions under investigation include: Adalimumab (DRUG).
Who is sponsoring clinical trial NCT06062875?
This trial is sponsored by Endeavor Health, which has 94 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06062875 being conducted?
This trial has 1 study location across Illinois. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Benign Prostatic Hyperplasia (BPH)
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.